| A Study of LY3337641 in Healthy Male Participants (NCT02914379) | Eli Lilly and Company | 2016-09-01 |
| A Study of LY2510924 and Durvalumab in Participants With Solid Tumors (NCT02737072) | Eli Lilly and Company | 2016-09-01 |
| A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants (NCT02917733) | Eli Lilly and Company | 2016-09-01 |
| A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer (NCT02677116) | Eli Lilly and Company | 2016-08-29 |
| A Study of LY3337641 in Rheumatoid Arthritis (NCT02628028) | Eli Lilly and Company | 2016-08-22 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780) | Eli Lilly and Company | 2016-08-10 |
| A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis (NCT02757352) | Eli Lilly and Company | 2016-08-02 |
| A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes (NCT02750410) | Eli Lilly and Company | 2016-08-01 |
| A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants (NCT02884089) | Eli Lilly and Company | 2016-08-01 |
| A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache (NCT02797951) | Eli Lilly and Company | 2016-07-13 |
| A Study of Galcanezumab in Healthy Participants. (NCT02836613) | Eli Lilly and Company | 2016-07-01 |
| A Study of LY3023414 Formulations and the Effect of Food (NCT02818335) | Eli Lilly and Company | 2016-07-01 |
| A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (NCT02791334) | Eli Lilly and Company | 2016-06-29 |
| A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia (NCT02791191) | Eli Lilly and Company | 2016-06-16 |
| A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors (NCT02718911) | Eli Lilly and Company | 2016-06-16 |
| A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer (NCT02734160) | Eli Lilly and Company | 2016-06-15 |
| A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease (NCT02760602) | Eli Lilly and Company | 2016-06-01 |
| A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (NCT02675231) | Eli Lilly and Company | 2016-05-23 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553) | Eli Lilly and Company | 2016-05-19 |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer (NCT02735980) | Eli Lilly and Company | 2016-05-11 |
| A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) (NCT02759107) | Eli Lilly and Company | 2016-05-11 |
| A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (NCT02696785) | Eli Lilly and Company | 2016-05-02 |
| A Study of Merestinib (LY2801653) in Healthy Participants (NCT02779738) | Eli Lilly and Company | 2016-05-01 |
| A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants (NCT02770521) | Eli Lilly and Company | 2016-05-01 |
| Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (NCT02605174) | Eli Lilly and Company | 2016-05-01 |
| A Study of Baricitinib (LY3009104) in Healthy Chinese Participants (NCT02758613) | Eli Lilly and Company | 2016-05-01 |
| A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) (NCT02754830) | Eli Lilly and Company | 2016-04-25 |
| A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis (NCT02696798) | Eli Lilly and Company | 2016-04-12 |
| Study of Galunisertib in Healthy Participants (NCT02752919) | Eli Lilly and Company | 2016-04-01 |
| A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants (NCT02752087) | Eli Lilly and Company | 2016-04-01 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis (NCT02718898) | Eli Lilly and Company | 2016-04-01 |
| A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) (NCT02708095) | Eli Lilly and Company | 2016-03-24 |
| A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body (NCT02688088) | Eli Lilly and Company | 2016-03-08 |
| A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy (NCT02703350) | Eli Lilly and Company | 2016-03-01 |
| A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia (NCT02714569) | Eli Lilly and Company | 2016-03-01 |
| A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy (NCT02703337) | Eli Lilly and Company | 2016-03-01 |
| A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps (NCT02703324) | Eli Lilly and Company | 2016-03-01 |
| A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma (NCT02659020) | Eli Lilly and Company | 2016-03-01 |
| A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer (NCT02555644) | Eli Lilly and Company | 2016-02-24 |
| A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies (NCT02572687) | Eli Lilly and Company | 2016-02-19 |
| A Study of Abemaciclib in Healthy Participants (NCT02677844) | Eli Lilly and Company | 2016-02-01 |
| A Study of Abemaciclib in Healthy Participants (NCT02672423) | Eli Lilly and Company | 2016-02-01 |
| A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis (NCT02576938) | Eli Lilly and Company | 2016-02-01 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment (NCT02634801) | Eli Lilly and Company | 2016-01-20 |
| A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes (NCT02588950) | Eli Lilly and Company | 2016-01-12 |
| A Study of LY3039478 in Healthy Participants (NCT02659865) | Eli Lilly and Company | 2016-01-01 |
| A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD (NCT02624778) | Eli Lilly and Company | 2015-12-22 |
| A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors (NCT02564198) | Eli Lilly and Company | 2015-12-11 |
| A Study of LY3090106 in Participants With Sjögren's Syndrome (SS) (NCT02614716) | Eli Lilly and Company | 2015-12-10 |
| A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis (NCT02589665) | Eli Lilly and Company | 2015-12-09 |
| Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (NCT02614196) | Eli Lilly and Company | 2015-12-04 |
| A Study of Mirikizumab (LY3074828) in Healthy Participants (NCT02568423) | Eli Lilly and Company | 2015-12-02 |
| A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD) (NCT02614131) | Eli Lilly and Company | 2015-12-01 |
| A Study of Various Formulations of LY900014 in Healthy Participants (NCT02636361) | Eli Lilly and Company | 2015-12-01 |
| Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (NCT02614183) | Eli Lilly and Company | 2015-11-30 |
| A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura (NCT02614287) | Eli Lilly and Company | 2015-11-30 |
| Evaluation of Galcanezumab in the Prevention of Chronic Migraine (NCT02614261) | Eli Lilly and Company | 2015-11-30 |
| A Study of LY3113593 in Participants With Chronic Kidney Disease (NCT02604160) | Eli Lilly and Company | 2015-11-17 |
| A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors (NCT02597036) | Eli Lilly and Company | 2015-11-06 |
| A Study of LY3200327 in Healthy Participants (NCT02595736) | Eli Lilly and Company | 2015-11-01 |
| A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (NCT02597049) | Eli Lilly and Company | 2015-11-01 |
| A Study of LY3154207 on Sleep in Healthy Male Participants (NCT02603861) | Eli Lilly and Company | 2015-11-01 |
| An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus (NCT02561078) | Eli Lilly and Company | 2015-10-20 |
| A Study of Galcanezumab in Healthy Participants (NCT02576951) | Eli Lilly and Company | 2015-10-19 |
| A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC (NCT02392507) | Eli Lilly and Company | 2015-10-12 |
| A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer (NCT02514551) | Eli Lilly and Company | 2015-10-12 |
| An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (NCT02565186) | Eli Lilly and Company | 2015-10-07 |
| A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma (NCT02539225) | Eli Lilly and Company | 2015-10-05 |
| A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (NCT02561806) | Eli Lilly and Company | 2015-10-01 |
| A Study of [¹⁴C]-LY3023414 in Healthy Participants (NCT02575703) | Eli Lilly and Company | 2015-10-01 |
| A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL (NCT02518113) | Eli Lilly and Company | 2015-10-01 |
| A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers (NCT02514603) | Eli Lilly and Company | 2015-10-01 |
| A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease (NCT02562768) | Eli Lilly and Company | 2015-09-30 |
| A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (NCT02451943) | Eli Lilly and Company | 2015-09-14 |
| A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis (NCT02584855) | Eli Lilly and Company | 2015-09-14 |
| A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC (NCT02451930) | Eli Lilly and Company | 2015-09-04 |
| A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants (NCT02543918) | Eli Lilly and Company | 2015-09-01 |
| A Study of LY3076226 in Participants With Advanced or Metastatic Cancer (NCT02529553) | Eli Lilly and Company | 2015-09-01 |
| A Study of LY3023414 in Japanese Participants With Advanced Cancer (NCT02536586) | Eli Lilly and Company | 2015-09-01 |
| A Study of [¹⁴C]-LY3202626 in Healthy Male Participants (NCT02555449) | Eli Lilly and Company | 2015-09-01 |
| A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NCT02450539) | Eli Lilly and Company | 2015-08-06 |
| A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis (NCT02513550) | Eli Lilly and Company | 2015-08-01 |
| A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer (NCT02441946) | Eli Lilly and Company | 2015-08-01 |
| A Study of a New LY900014 Formulation in Healthy Participants (NCT02525744) | Eli Lilly and Company | 2015-08-01 |
| A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (NCT02443324) | Eli Lilly and Company | 2015-07-29 |
| A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (NCT02435433) | Eli Lilly and Company | 2015-07-20 |
| A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (NCT02426125) | Eli Lilly and Company | 2015-07-13 |
| A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer (NCT02443883) | Eli Lilly and Company | 2015-07-07 |
| A Study of Cephalexin Liquid in Healthy Participants (NCT02490670) | Eli Lilly and Company | 2015-07-01 |
| A Study of Different Particle Sizes of Evacetrapib in Healthy Participants (NCT02497391) | Eli Lilly and Company | 2015-07-01 |
| A Study of LY3023414 and Necitumumab in Squamous Lung Cancer (NCT02443337) | Eli Lilly and Company | 2015-07-01 |
| A Study of Galcanezumab in Participants With Chronic Cluster Headache (NCT02438826) | Eli Lilly and Company | 2015-06-18 |
| A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT02411591) | Eli Lilly and Company | 2015-06-04 |
| A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food (NCT02482935) | Eli Lilly and Company | 2015-06-01 |
| A Study Of Galcanezumab In Participants With Episodic Cluster Headache (NCT02397473) | Eli Lilly and Company | 2015-05-22 |
| A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY) (NCT02411448) | Eli Lilly and Company | 2015-05-06 |
| A Study of Galunisertib on the Immune System in Participants With Cancer (NCT02304419) | Eli Lilly and Company | 2015-05-01 |
| A Study of LY3022855 In Participants With Breast or Prostate Cancer (NCT02265536) | Eli Lilly and Company | 2015-05-01 |
| A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer (NCT02407054) | Eli Lilly and Company | 2015-04-29 |
| A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain (NCT02308020) | Eli Lilly and Company | 2015-04-20 |